The use of erythropoietin.
EPO is a hematopoietic growth factor produced in the kidney that stimulates erythropoiesis. It effectively treats hypoproliferative anemia associated with CRF, improving quality of life in these patients. Other uses that are poorly characterized in veterinary medicine include treatment of cancer patients on chemotherapy, hematologic disorders, and anemic FeLV-infected cats as well as preoperative conditioning for elective surgeries that may involve significant blood loss. Careful monitoring of therapy is necessary for optimal results. Several complications are associated with rHuEPO therapy. The production of anti-rHuEPO antibodies is the most significant and can be a life-threatening event. Alternatives to human EPO are being sought to provide beneficial effects while avoiding antibody formation.
Langston
Cathy E
CE
Department of Medicine, Animal Medical Center, 510 East 62nd Street, New York, NY 10021, USA. cathy.langston@amcny.org
Reine
Nyssa J
NJ
Kittrell
Dianne
D
D000740:Anemia / Q000188:drug therapy / Q000662:veterinary*; D000818:Animals; D002371:Cat Diseases / Q000188:drug therapy*; D002415:Cats; D017024:Chemotherapy, Adjuvant; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004921:Erythropoietin / Q000627:therapeutic use*; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D004921:Erythropoietin